Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Brief Summary: The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis


Options:
A: Inclusion Criteria:

* Physician diagnosis of atopic dermatitis for greater than (\>) 1 year
* Atopic dermatitis involvement of greater than or equal to (\>=) 10 percent (%) body surface area
* EASI score of \>= 12
* SCORAD of \>= 25
* IGA score of \>= 3
* Effective birth control in line with protocol details

Exclusion Criteria:

* History of anaphylaxis following any biologic therapy
* Hepatitis B, C or human immunodeficiency virus
* Pregnant or breastfeeding
* History of cancer
* Previous receipt of tralokinumab
B: Inclusion Criteria:

* AD meeting Hanifin and Rajka criteria
* Age 18-75 years inclusive at screening
* Atopic dermatitis that affects greater than/equal to 10% body surface area
* Moderate to severe AD
* Effective birth control in line with protocol details

Exclusion Criteria:

* Active dermatologic conditions which may confuse the diagnosis of Atopic Dermatitis
* Hepatitis B, C or HIV
* Pregnant or breastfeeding
* History of anaphylaxis following any biologic therapy
* History of clinically significant infections within 4 weeks prior to Visit 3
* Diagnosis of helminth parasitic infection within 6 months to screening
* History of Cancer except basal cell
* Receipt of any marketed or investigational biologic agent within 4 months to visit 3
* Any clinically relevant abnormal finding
* Major surgery within 8 weeks prior to Visit 1
C: Inclusion Criteria:

* ≥18 and ≤65 years of age at the time of consent.
* Patients with Atopic Dermatitis
* Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit
* Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit
* static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit

Exclusion Criteria:

* Serological evidence of hepatitis B virus or hepatitis C virus infection
* Known human immunodeficiency virus infection
* Ongoing treatment with specific or non-specific hyposensitization therapy for AD
* Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week prior to randomization
* History of infection including skin infection requiring treatment with oral or intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to randomization.
* Evidence of tuberculosis (TB) infection as defined by a positive purified protein derivative (PPD) and/or positive interferon-gamma release assay.
* Pregnant or lactating women.
D: Inclusion Criteria:

* Clinical diagnosis of atopic dermatitis that has been present for at least 3 years before the screening visit
* Investigator's Global Assessment (IGA) score of \>/= 3 at the screening and baseline visits
* \>/= 15% body surface area (BSA) of AD involvement at the screening and baseline visits
* History of inadequate response to a stable (\>/= 1 month) regimen of topical corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before the screening visit
* Willing and able to comply with clinic visits and study-related procedures
* Patient able to read and understand, and willing to sign the informed consent form

Exclusion Criteria:

* A positive QuantiFERON® - TB (tuberculosis) Gold Test at the screening visit
* Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C and/or positive Hepatitis B surface antigen (HBsAg), positive Hepatitis C antibody (HCV)
* Treatment with an investigational drug within 8 weeks before the baseline visit
* Treatment with leukotriene inhibitors within 4 weeks before the baseline visit
* Treatment with systemic corticosteroids within 4 weeks before the baseline visit
* Treatment with topical corticosteroids, tacrolimus, and/or pimecrolimus within 1 week before the baseline visit
* Systemic treatment for AD with an immunosuppressive/immunomodulating substance within 4 weeks before the baseline visit
* Chronic or acute infection requiring treatment
* History of clinical parasite infection, other than treated trichomoniasis
* History of malignancy within 5 years before the baseline visit
* Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results
* Pregnant or breast-feeding women
* Unwilling to use adequate birth control, if of reproductive potential and sexually active

Answer: A